Form 4: Compass Therapeutics CEO Thomas Schuetz Reports Stock Transaction
SEC Form 4 Filing
Compass Therapeutics CEO Thomas Schuetz sold 58,054 shares to cover tax obligations related to vesting restricted stock units.
Summary
- Thomas J. Schuetz, CEO of Compass Therapeutics, reported a transaction involving the company's common stock.
- On January 9, 2025, Mr. Schuetz disposed of 58,054 shares of common stock at a price of $1.86 per share.
- This transaction was to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
- Following the transaction, Mr. Schuetz beneficially owns 6,512,512 shares of Compass Therapeutics stock.
- The reported holdings include unvested RSUs granted on November 16, 2021, February 8, 2023, and January 9, 2024, which vest in four equal annual installments.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing for an insider stock transaction, which is neither positive nor negative for the company's outlook. It is a neutral event.
Industry Context
This is a standard SEC Form 4 filing, which is common for company insiders who trade their company's stock. It provides transparency into the transactions of key personnel.
Comparison to Industry Standards
- SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
- The transaction is typical for executives who receive stock-based compensation, often selling shares to cover tax liabilities upon vesting.
- The number of shares sold is relatively small compared to the total shares owned by the CEO, suggesting this is a routine transaction rather than a significant change in ownership.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale of shares by an executive to cover tax obligations.
- The transaction does not impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 11/16/2021 | Date of grant for 150,000 unvested RSUs, vesting in four equal annual installments starting November 15, 2022. |
| 02/08/2023 | Date of grant for 375,000 unvested RSUs, vesting in four equal annual installments starting February 8, 2024. |
| 01/09/2024 | Date of grant for 478,125 unvested RSUs, vesting in four equal annual installments starting January 9, 2025. |
| 01/09/2025 | Date of the stock transaction where 58,054 shares were disposed of. |
| 01/13/2025 | Date the SEC Form 4 was signed by Thomas J. Schuetz. |
Keywords
Compass Therapeutics, Thomas Schuetz, stock transaction, SEC Form 4, restricted stock units, RSUs, insider trading, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.